← Drug library

Levetiracetam

KeppraAntiseizure medicationImmediate release tablet, extended release tablet, oral solution, and injection

Mechanism

Its precise antiseizure mechanism is not fully established. Binding to synaptic vesicle protein SV2A may help regulate vesicle exocytosis and contribute to its antiseizure activity.

Uses

  • Partial-onset seizures
  • Myoclonic seizures in juvenile myoclonic epilepsy
  • Primary generalized tonic-clonic seizures

Administration

  • Immediate release products are generally divided into twice-daily administration
  • Pediatric dosing depends on age and body weight
  • Adult dosing must be adjusted for renal impairment
  • Avoid abrupt withdrawal because seizure frequency and status epilepticus can increase

Common effects

  • Somnolence
  • Fatigue or asthenia
  • Dizziness
  • Behavioral changes or irritability

Serious risks

  • Suicidal thoughts or behavior
  • Psychotic symptoms or marked behavioral change
  • Anaphylaxis or angioedema
  • Serious skin reactions and DRESS
  • Withdrawal seizures

Contraindications

  • Known hypersensitivity to levetiracetam, including previous anaphylaxis or angioedema

Interactions

  • Clinically important CYP-mediated pharmacokinetic interactions are unlikely
  • Label studies found no meaningful pharmacokinetic effect with phenytoin, valproate, warfarin, digoxin, or a studied combined oral contraceptive
  • Review concomitant medicines that may worsen somnolence or impaired coordination

Monitoring

  • Seizure frequency and adherence
  • Mood, behavior, and suicidal thinking
  • Somnolence, gait, and coordination
  • Renal function for dose selection
  • Rash, fever, or evidence of systemic hypersensitivity

Counseling

  • Do not stop the medication abruptly
  • Avoid driving until individual effects are understood
  • Report new aggression, depression, unusual behavior, or suicidal thoughts promptly
  • Seek care for facial swelling, breathing difficulty, rash, fever, or swollen lymph nodes
PharmacyOpen tools